Latest News

Dasatinib Plus Chemo Achieves Long-Term Remission in Ph+ Acute Leukemia

Dasatinib Plus Chemo Achieves Long-Term Remission in Ph+ Acute Leukemia

Combination of chemotherapy with dasatinib is effective in achieving long-term remission for in Ph+ acute lymphoblastic leukemia (ALL).

Patupilone Shows Activity in Recurrent NSCLC Brain Metastases

Patupilone Shows Activity in Recurrent NSCLC Brain Metastases

Patupilone demonstrated activity in heavily pretreated patients with recurrent brain metastases from non-small cell lung cancer (NSCLC).

How Many People Does it Take to Increase Colorectal Cancer Screening to 80%?

How Many People Does it Take to Increase Colorectal Cancer Screening to 80%?

Approximately 277,000 colorectal cancer (CRC) cases and 203,000 CRC deaths can be averted if screening and prevalence to 80% is reached.

Blood Test May Predict Relapse in Early-Stage Breast Cancer

Blood Test May Predict Relapse in Early-Stage Breast Cancer

An experimental blood test may one day detect the return of early-stage breast cancer months before it is revealed.

ERCC1 Genotype Can Identify Good Prognosis in Nasopharyngeal Cancer

ERCC1 Genotype Can Identify Good Prognosis in Nasopharyngeal Cancer

Excision repair cross-complementing group 1 (ERCC1) genotype may identify favorable prognosis for subgroup of nasopharyngeal carcinoma (NPC).

Most Women Experience Anxiety With False-Positive Mammograms

Most Women Experience Anxiety With False-Positive Mammograms

A majority of women who receive false positives on mammography experience distress and anxiety.

Daratumumab Monotherapy Shows Promise for Multiple Myeloma

Daratumumab Monotherapy Shows Promise for Multiple Myeloma

Daratumumab monotherapy has a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma.

Higher Travel Burden, Non-private Insurance Linked With Less Likelihood for Adjuvant Chemo

Higher Travel Burden, Non-private Insurance Linked With Less Likelihood for Adjuvant Chemo

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy for treatment of colon cancer.

Hypertension Not a Predictor for Pazopanib Efficacy

Hypertension Not a Predictor for Pazopanib Efficacy

Pazopanib-induced hypertension did not correlate with outcome in pazopanib-treated soft tissue sarcoma patients.

Ibandronate May Be Alternative to Radiotherapy for Metastatic Prostate Bone Pain

Ibandronate May Be Alternative to Radiotherapy for Metastatic Prostate Bone Pain

A single infusion of ibandronate had outcomes similar to a single dose of radiotherapy for metastatic bone pain in prostate cancer.

No Association Between Common Genetic Mutations, Prostate Cancer Survival

No Association Between Common Genetic Mutations, Prostate Cancer Survival

There is no association between common genetic variants and prostate cancer survival.

In Breast Cancer Survivors, Acupuncture Better Than Pills for Hot Flashes

In Breast Cancer Survivors, Acupuncture Better Than Pills for Hot Flashes

Acupuncture appears to be more efficacious than oral medication for treating hot flashes in breast cancer survivors.

Electronic Intervention May Reduce Time to Diagnostic Evaluation

Electronic Intervention May Reduce Time to Diagnostic Evaluation

Electronic trigger-based interventions appear to be effective in reducing time to diagnostic evaluation of colorectal and prostate cancers.

In Follicular Lymphoma, Adding Rituximab to Lenalidomide May Improve Activity

In Follicular Lymphoma, Adding Rituximab to Lenalidomide May Improve Activity

Lenalidomide plus rituximab is more active than lenalidomide alone in patients with recurrent follicular lymphoma with similar toxicity.

Adding Trebananib to Sunitinib May Improve Renal Cell Carcinoma Outcomes

Adding Trebananib to Sunitinib May Improve Renal Cell Carcinoma Outcomes

The addition of trebananib to sunitinib may provide a benefit to patients with metastatic clear cell renal cell carcinoma.

Regorafenib Not Cost-effective for Third-line Treatment of Colorectal Cancer

Regorafenib Not Cost-effective for Third-line Treatment of Colorectal Cancer

Regorafenib for third-line management of metastatic colorectal cancer may provide minimal incremental benefit at high incremental cost.

Music May Reduce Anxiety Score in Breast Cancer Surgery Patients

Music May Reduce Anxiety Score in Breast Cancer Surgery Patients

Live and recorded perioperative music therapy reduces anxiety in patients undergoing surgery for potential or known breast cancer.

Circulating Tumor Cell Assays May Play Role in Bladder Cancer Management

Circulating Tumor Cell Assays May Play Role in Bladder Cancer Management

Circulating tumor cell assays may have a role in the management of bladder cancer.

Low-Dose Aspirin, NSAIDs May Lower Colorectal Cancer Risk

Low-Dose Aspirin, NSAIDs May Lower Colorectal Cancer Risk

Regularly taking low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may lower long-term risk of colorectal cancer (CRC).

FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma

FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma

The FDA has granted Breakthrough Therapy Designation to cabozantinib as a potential treatment for advanced renal cell carcinoma (RCC).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs